ArticleCardio-oncology (London, England)2026
Electrocardiographic predictors of major adverse cardiovascular events in immune checkpoint inhibitor-associated myocarditis.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early lymphocyte recovery predicts cardiovascular events and mortality in immune checkpoint inhibitor-associated myocarditis: a retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitor (ICI)–associated myocarditis carries a high risk of mortality, yet electrocardiographic (ECG) predictors of adverse outcomes remain unclear. The present study aimed to evaluate the predictive value of clinical and admission ECG parameters for major adverse cardiovascular events (MACE).
methodsWe retrospectively analyzed 60 consecutive patients with ICI myocarditis. Patients were stratified according to the occurrence of major adverse cardiovascular events (MACE), defined as myocarditis-related cardiogenic shock, high-degree atrioventricular block requiring temporary or permanent pacing, or sustained ventricular tachycardia(VT)/ventricular fibrillation(VF). Admission ECGs were systematically adjudicated for conduction and repolarization abnormalities, and an ECG burden score (0–6) was derived. Univariable and multivariable Firth penalized Cox regression models were used to identify predictors of MACE. Model performance was evaluated using discrimination and reclassification metrics across nested models: M1 (clinical variables), M2 (M1 + biomarkers and echocardiography), and M3 (M2 + ECG burden score).
resultsAmong the 60 patients with myocarditis, MACE occurred in 21 patients (35%) patients. Compared with the non-MACE group, QTc prolongation (p = 0.011), QRS ≥ 120 ms((p = 0.002), Atrioventricular block (p = 0.007), bundle branch block (p = 0.005), ST-segment abnormalities (p = 0.003), and T-wave changes (p = 0.004) at the time of admission were more common in the MACE group. In multivariable Firth penalized Cox analysis, severe myocarditis, QTc prolongation, Atrioventricular block, QRS ≥ 120 ms, ST-segment abnormalities, T-wave changes, and higher ECG burden score independently predicted MACE. Sensitivity analyses excluding early MACE or in-hospital deaths confirmed robustness of results. Addition of ECG variables significantly improved model performance (C-index 0.726 [M1] vs. 0.860 [M2] vs. 0.941 [M3]), with significant net reclassification and integrated discrimination gains.
conclusionAdmission ECG abnormalities are powerful, independent predictors of adverse outcomes in ICI myocarditis and provide substantial incremental prognostic value beyond clinical and biomarker/echocardiographic features. Systematic ECG assessment and integration into risk stratification should be prioritized for early triage and monitoring in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.